According to Genesis, the cinematic project marks a continuation of the brand’s cultural programming celebrating the centennial of Marilyn Monroe’s birth, linking Monroe’s legacy of breaking boundaries with the automaker’s global luxury identity.
Film Production and Creative Team
“Flesh Impact” features a prominent Hollywood cast and crew assembled through a collaboration with Authentic Brands Group, the owner and manager of the Marilyn Monroe estate. Maggie Gyllenhaal directs the feature, which explores Monroe’s life and impact from modern perspectives. The cast includes Dakota Johnson portraying Monroe during her early years of peak fame, and Academy Award-winning actress Ellen Burstyn depicting Monroe in later life. Peter Sarsgaard and Sepideh Moafi also hold roles in the production.
According to Gyllenhaal, the collaboration began when Genesis approached the team with the proposal to commemorate the Monroe centennial. “This film is a contemporary reinterpretation of the Marilyn Monroe we remember and love, designed to shed fresh light on her narrative,” Gyllenhaal stated.
Brand Strategy and Exhibition Context
The film support expands on Genesis’s ongoing “Manifesting Marilyn” exhibition, which opened in June at Genesis House in New York. The exhibition is structured to present Monroe’s personal and professional history to audiences. Amy Marentic, chief marketing officer of Genesis Motor North America, stated that the brand believes art creates meaningful human connections, framing the film sponsorship as a commitment to highlighting cultural icons with enduring influence.
The title “Flesh Impact” derives from descriptions of Monroe’s physical presence and screen aura, intended to convey a direct connection between the actor and the audience. The project represents a bridge between corporate cultural sponsorship and biographical filmmaking.
Festival Premiere and Timeline
The world premiere of “Flesh Impact” is set for the Venice International Film Festival in September 2026. The festival screening will serve as the initial public release for the Gyllenhaal-directed biopic before wider distribution plans are finalized.
Related reading
- Samsung Galaxy S26 FE Deal: Now Under €750 on Amazon
- 25,000 Years of Rituals Discovered in Australian Cave
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)